Eysuvis (Loteprednol Etabonate) Patent Expiration, LOE Window & CMS Spending

Eysuvis (Loteprednol Etabonate) by Novartis: FDA Orange Book LOE 2033-05-03, 9 AB generics, $17.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN210933 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-05-03
Orange Book Patents (*PED Extensions)17 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$17.6M
2024 Medicare Part D Spend$12.9M
2024 Medicaid Spend$4.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.